BIW-8962

DRUG2 trials

Sponsors

Kyowa Kirin Co., Ltd., Kyowa Kirin Korea Co., Ltd.

Conditions

Multiple MyelomaPhase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), MesotheliomaPhase 2 Portion : Small Cell Lung Cancer(SCLC)

Phase 1

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

TerminatedNCT00775502

Kyowa Kirin Co., Ltd.Multiple Myeloma

Start: 2008-10-31End: 2011-10-31Updated: 2024-04-25

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

TerminatedNCT01898156

Kyowa Kirin Korea Co., Ltd.Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma, Phase 2 Portion : Small Cell Lung Cancer(SCLC)

Start: 2013-07-31End: 2016-06-30Updated: 2024-04-25

Related Papers

Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.

2016-11-025 citations